Dual detection of Legionella pneumophila and Legionella species by real-time PCR targeting the 23S-5S rRNA gene spacer region  by Yang, G. et al.
Dual detection of Legionella pneumophila and Legionella species by
real-time PCR targeting the 23S-5S rRNA gene spacer region
G. Yang, R. Benson, T. Pelish, E. Brown, J. M. Winchell and B. Fields
Respiratory Diseases Branch, Division of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA
Abstract
Although the majority of cases of Legionnaires’ disease (LD) are caused by Legionella pneumophila, an increasing number of other Legio-
nella species have been reported to cause human disease. There are no clinical presentations unique to LD and hence accurate labora-
tory tests are required for early diagnosis. Therefore, we designed a real-time PCR assay that targets the 23S-5S rRNA intergenic
spacer region (23S-5S PCR) and allows for detection of all Legionella species and discrimination of L. pneumophila from other Legionella
species. In total, 271 isolates representing 50 Legionella species were tested and the assay was validated using 39 culture-positive and
110 culture-negative patient specimens collected between 1989 and 2006. PCR-positive results were obtained with all 39 culture-posi-
tive samples (100% sensitivity). Specimens that tested positive according to 23S-5S PCR, but were culture-negative, were further analy-
sed by DNA sequencing of the amplicon or the macrophage infectivity potentiator (mip) gene. In addition to L. pneumophila, Legionella
longbeachae, Legionella cincinnatiensis and Legionella micdadei were identiﬁed in the specimens. The assay showed a 7-log dynamic range
displaying a sensitivity of 7.5 CFU/mL or three genome equivalents per reaction. Sixty-one specimens containing viruses or bacteria
other than Legionellae were negative according to 23S-5S PCR, demonstrating its speciﬁcity. Use of this assay should contribute to the
earlier detection of respiratory disease caused by Legionella species, as well as to increased rates of detection.
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Introduction
Legionellae are ubiquitous in natural and man-made aqueous
environments. To date, at least 52 Legionella spp. have
been identiﬁed (http://www.bacterio.cict.fr/l/legionella.html).
Twenty-three species have been found to be associated with
human diseases [1,2]. Approximately 80–90% of reported
cases of Legionnaires’ disease (LD) are attributed to Legionel-
la pneumophila; however, all species may cause infection,
especially in immunocompromised hosts [1,3,4].
Legionnaires’ disease has no unique clinical or radiographic
features [5,6], which may lead to inappropriate therapy and a
poor prognosis. Therefore, a validated and rapid diagnostic
assay is of great importance. Current laboratory criteria for
ensuring a conﬁrmed diagnosis of LD involve isolating Legio-
nellae by culture and detecting L. pneumophila serogroup 1
antigen in urine or seroconversion. Although these method-
ologies have good speciﬁcity, they primarily detect L. pneu-
mophila. Non-pneumophila Legionella spp. may grow on
buffered charcoal yeast extract (BCYE) media, but it usually
takes approximately 1–2 weeks of incubation time for identi-
ﬁcation. Some strains, such as Legionella-like amoebal patho-
gens, are very fastidious and require amoebal co-culture [7],
which is laborious and impractical for clinical diagnosis.
Therefore, infections caused by non-pneumophila species may
not be diagnosed.
To address these deﬁciencies, molecular assays that target
the nucleic acid of Legionellae have been developed, but their
applications in clinical diagnosis are still limited. For example,
the proportion of cases diagnosed by PCR and other geno-
typic methods in Europe from 1995 to 2004 accounts for
< 2% of cases of LD (n = 27 244) [8]. Reluctance to use
PCR assays for diagnosis is partially attributable to: (i) post-
ampliﬁcation procedures that are laborious, time-consuming
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases
ORIGINAL ARTICLE 10.1111/j.1469-0691.2009.02766.x
and prone to carry-over contamination and false positivity,
and (ii) limited assay optimization and validation. Here, we
present a real-time PCR assay that allows rapid detection
and differentiation of L. pneumophila from 50 non-pneumophil-
a species without the need for post-PCR manipulation. The
assay has been optimized to ensure sensitivity and speciﬁcity
and validation has been carried out using culture isolates and
clinical specimens. This assay should increase the rate of
detection of infection caused by non-pneumophila strains of
Legionellae and contribute to early diagnosis of LD.
Materials and Methods
Bacterial and viral strains
Viruses and bacteria other than Legionellae were used to test
the speciﬁcity of the real-time PCR, including Bordetella
pertussis, Bordetella parapertussis, Bordetella holmesii, Bordetella
bronchiseptica, Corynebacterium diphtheriae, Candida albicans,
Chlamydophila pneumoniae, Chlamydia psittaci, Chlamydia tracho-
matis, Escherichia coli, Haemophilus inﬂuenzae, Mycoplasma
pneumoniae, Mycoplasma hominis, Mycoplasma genitalium,
Ureaplasma urealyticum, Mycoplasma arginini, Mycoplasma
buccale, Mycoplasma faucium, Mycoplasma fermentans, Myco-
plasma hyorhinis, Mycoplasma lipophilum, Mycoplasma orale,
Mycoplasma penetrans, Mycoplasma pirum, Mycoplasma salivari-
um, Moraxella catarrhalis, Mycobacterium tuberculosis, Neisseria
meningitidis, Neisseria elongata, Pseudomonas aeruginosa, Strep-
tococcus pneumoniae, Streptococcus pyogenes, Streptococcus sali-
varius, Streptococcus oligofermentans, Streptococcus sustralis,
Streptococcus vestibularis, Streptococcus sinesis, Streptococcus
gordonii, Streptococcus agalactiae, Streptococcus peroris, Strepto-
coccus sanguinis, Streptococcus parasanguinis, Streptococcus in-
fantis, Streptococcus mitis, Streptococcus cristatus, Streptococcus
oralis, Klebsiella pneumoniae, Staphylococcus aureus, Staphylococ-
cus epidermidis, inﬂuenza A (H1, H3, H5), inﬂuenza B, severe
acute respiratory syndrome (SARS), respiratory syncytial
virus (A, B), human parainﬂuenza viruses (1, 2, 3), human
metapneumovirus, and adenovirus. Each was cultured using
appropriate agar, cells and medium.
Legionella strains were grown on BCYE agar at 35 C with
2.5% CO2 for 48–72 h. The incubation period for the culture
of human specimens was 7 days. The bacteria derived from a
single colony were harvested in water and subjected to
genomic DNA puriﬁcation.
Primers and probe design, synthesis and optimization
Primers targeting the 23S-5S rRNA intergenetic spacer
region conserved for all Legionella species were designed.
The sequences of forward and reverse primers were 5¢-GTA
CTA ATT GGC TGA TTG TCT TGA CC-3¢ and 5¢-CCT
GGC GAT GAC CTA CTT TCG-3¢, respectively. Two
probes were designed within the amplicon region. One is
speciﬁc for L. pneumophila (5¢-CalOrg-ATC GTG TAA ACT
CTG ACT CTT TAC CAA ACC TGT GG-3¢BHQ); the
other recognizes all known Legionella species (5¢-FAM ATC
TC‘‘G’’ AA‘‘C’’ T‘‘C’’A ‘‘G’’AA ‘‘G’’T‘‘G’’ AAA C-3¢BHQ)
(‘‘’’ denotes lock nucleic acid) and is referred to as the
genus-wide probe or Legionella spp. probe.
All PCR reactions were performed in triplicate using the
AgPath-ID One-Step RT-PCR kit (AM1005; Applied Biosys-
tems, Inc., Foster City, CA, USA) and the 7900HT real-time
PCR system (Applied Biosystems, Inc.) unless otherwise indi-
cated.
Standard curve analysis and sensitivity determination
Genomic DNA was puriﬁed from L. pneumophila serogroup 1
using the KingFisher ML instrument (Thermo Fisher Scientiﬁc,
Inc., Waltham, MA, USA) and the InviMag kit (B-Bridge Inter-
national, Inc., Sunnyvale, CA, USA) following the manufactur-
ers’ instructions. Genome equivalent (gEq), or single copy of
genome, was calculated using a genome size of 3.397 · 106 bp
(GenBank accession no. NC_002942). Ten-fold serial dilutions
of the genomic DNA spanning seven orders of magnitude
were ampliﬁed using optimized primers and probes.
To determine the lower limit of detection (LLOD) for live
bacteria, ten-fold serial dilutions of L. pneumophila serogroup
1 were streaked on BCYE plates. Bacterial colonies were
manually counted. Colony counts of > 120 or < 20 were
excluded from analysis. The bacteria were suspended in
water and diluted to c. 100 CFU/mL. Genomic DNA was
extracted as above from 1.5 mL of bacterial suspension. Five
per cent of the puriﬁed DNA samples (n = 30) correspond-
ing to c. 7.5 CFU/mL were ampliﬁed using the 7900HT real-
time PCR system.
Clinical specimens
In total, 149 clinical specimens from 67 patients with respira-
tory disease possibly caused by Legionella infection were
tested. The specimens were collected over a 17-year period
(Table 1). Cultures were performed on BCYE or selective
media upon receipt. Retrospective studies were carried out
using the remaining specimens, which had been stored at
) 80 C, to validate the 23S-5S PCR assay. Analysis of the
mip sequence was performed on all culture-negative, but
PCR-positive, samples unless otherwise indicated (Table 1)
using the 3130XL Sequencer and BigDye X Terminator
reagent and puriﬁcation kit (Applied Biosystems, Inc.). The
sequences were aligned with those in the National Center
for Biotechnology Information (NCBI) database or the
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online mip-based Legionella identiﬁcation tool (http://www.
hpa-bioinfotools.org.uk/mip_ID.html). Real-time PCR for the
human RNase P gene was carried out in parallel to monitor
reaction inhibition and DNA integrity.
Results
Detection of Legionella spp. in clinical specimens
The 149 patient specimens corresponded to 11 sample types
(Table 1). The assay allowed detection of Legionella spp. in all
39 culture-positive specimens. Moreover, Legionellae were
identiﬁed in 27 of 110 culture-negative samples. Specimens
that were 23S-5S PCR-positive but culture-negative were con-
ﬁrmed by sequencing the amplicon or by amplifying the mip
gene, which was subsequently sequenced [9]. Among the 27
culture-negative samples, 15 were positive for L. pneumophila,
two were positive for Legionella longbeachae, one was positive
for Legionella cincinnatiensis and one was positive for Legionella
micdadei. Amplicon sequence analysis of mip or 23S-5S did not
reveal signiﬁcant homology with any known Legionella spp.
in seven samples, suggesting potentially novel Legionella spp.
(R. M. Ratcliff, personal communication, 2008). One sample
was depleted and no sequence analysis was performed.
Assay design and optimization
One set of primers and two probes were designed within
the same region, resulting in a singleplex dual-colour real-
time PCR (Fig. 1a). PCR reactions were performed using the
primers at working concentrations of 25–200 nM at two-fold
intervals. The sensitivity was three orders of magnitude
lower if the primer concentration was < 100 nM. The lowest
cycle threshold (Ct) occurred with forward/reverse primers
at 100 nM and 200 nM, respectively. Increasing the concen-
tration from 200 nM to 800 nM did not improve sensitivity
as Ct values remained nearly unchanged (p < 0.05). The
probes were titrated similarly from 50 nM to 600 nM. Use
of the Legionella spp. probe at a concentration of 200 nM
gave the best performance and increasing the concentration
to 400 nM did not reduce the Ct values. The L. pneumophila-
speciﬁc probe performed better at 400 nM. Higher probe
concentration resulted in decreased sensitivity (data not
shown).
Ampliﬁcation efﬁciency, reproducibility and sensitivity
Linear regression analysis of the standard curves showed
excellent correlation between the Ct value and the copy
number of the Legionella genome (R2 = 0.997) over seven
orders of magnitude. The efﬁciency of ampliﬁcation was
100.7% and 102.6% for L. pneumophila and the genus-wide
assays, respectively (Fig. 1b). The primers target the speciﬁc
sites, even in the presence of high concentrations of Legionel-
la genomic DNA (Fig. 1c).
The analytical sensitivity was assessed by amplifying
L. pneumophila serogroup 1 DNA at a concentration of
3 gEq per PCR reaction. All samples were positive using the
Legionella spp. probe (n = 20; Ct = 34.59 ± 0.76, coefﬁcient
of variation (CV) 2.22%) and 95% of the samples were
TABLE 1. Clinical specimens for validating 23S-5S assay
Sample type
Cultures
positive
(+), n
PCR
positive
(+), n
PCR
negative
()), n
Cultures
())/PCR (+), n
mip sequence analysis
of PCR+ but culture)
samplesa Total
Sputum 9 18 40 9 L. pneumophila (n = 5)
L. longbeachae (n = 2)
L. cincinnatiensis (n = 1)
Novel Legionella spp. (n = 1)
58
Lung tissue 24 31 28 7 L. pneumophila (n = 6)
Undetermined (n = 1)b
59
Bronchoalveolar lavage 2 3 4 1 L. micdadei (n = 1) 7
Bronchial swab 2 2 0 0 Not applicable 2
Nasopharyngeal swab 2 2 0 0 Not applicable 2
Blood 0 8 0 8 L. pneumophila (n = 2)
Novel Legionella spp.(n = 6)
8
Liver 0 0 1 0 Not applicablec 1
Trans-tracheal aspirate 0 0 1 0 Not applicablec 1
Spleen 0 0 1 0 Not applicablec 1
Pleural ﬂuid 0 1 1 1 L. pneumophila (n = 1)d 2
Formalin-ﬁxed and parafﬁn
embedded tissue (FFPE)
0 1 7 1 L. pneumophila (n = 1)d 8
Total number of specimens 39e 66 83 27 27 149
Percentage of specimens 26% 44% 56% 18% 18% 100.0%
amip sequence analysis for all culture)/PCR+ samples unless otherwise indicated.
bNo sample left for sequencing.
cNot applicable for sequence analysis.
dAmplicon sequence analysis only.
ePositive for Legionella pneumophila.
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positive using the L. pneumophila probe (n = 20;
Ct = 35.51 ± 0.96, CV = 2.69%). By contrast, no signals
were detected from no-template controls (NTCs) (n > 100)
after 40 cycles of ampliﬁcation. Therefore, the LLOD of the
assay was c. 3 gEq per PCR reaction. For live bacteria, the
assay detected L. pneumophila serogroup 1 at 7.5 CFU/mL
(n = 30; for the Legionella spp. probe: Ct = 33.83 ± 0.52,
CV = 1.53%; for the L. pneumophila probe: Ct = 37.05 ±
0.92, CV = 2.48%). No ampliﬁcation was detected in the
NTCs (n = 10).
Accuracy and speciﬁcity
Genomic DNA isolated from the 271 strains representing
the 50 Legionella spp. listed in Table 2 were ampliﬁed and
detected using the Legionella spp. probe and the L. pneumo-
phila-speciﬁc probe. The L. pneumophila probe did not cross-
react with any non-pneumophila species and accurately
detected L. pneumophila, despite the presence of high con-
centrations of genomic DNA.
Total nucleic acid (TNA) was puriﬁed from 61 bacterial
and viral strains (listed in Materials and methods). The TNA
quality was demonstrated by corresponding PCR ampliﬁca-
tions. Although the concentration of the templates was rela-
tively high (5 ng, or c. 1 · 107 gEq for an organism with a
genome size of 3.0 · 106 bp (GenBank accession no.
NC_002942), none of the strains reacted with the Legionella
probes, yielding an analytical speciﬁcity of 100%.
Discussion
The urine antigen (UA) test is increasingly used by clinicians
in the diagnosis of LD, but it is limited to the detection of
L. pneumophila serogroup 1 [10]. Extensive use of the UA
test has resulted in a decrease in the use of other diagnostic
methods, thus reducing the frequency of identiﬁcation of
species other than L. pneumophila serogroup 1 [11]. For
example, a recent study of population-based surveillance of
severe pneumonia in Thailand found no cases of L. pneumo-
phila serogroup 1 infection using a UA test, but serological
evidence suggested that approximately 5% of cases of pneu-
monia may be caused by L. longbeachae (n = 397) [12]. This
underscores the need for diagnostic tests for all Legionella
spp. In this study, we developed and validated a 23S-5S dual-
colour real-time PCR assay. The LLOD of the assay was
3 gEq/reaction for genomic DNA or 7.5 CFU/mL for the live
Legionella strain. It can distinguish L. pneumophila from non-
pneumophila Legionella spp. and can detect Legionella spp.
from all culture-positive clinical specimens within 3 h without
requiring post-PCR processing steps. We assessed the speci-
ﬁcity of the assay by analysing the DNA sequence of the
amplicon or the mip gene and by assessing the reactivity with
the non-Legionella bacteria and viruses.
Legionella is not part of the human ﬂora; thus, the pres-
ence or absence of Legionella DNA in specimens could be
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FIG. 1. Assay design and standard curve analysis. (a) Schematic diagram of the design of the primers and probes. The forward/reverse primers
were selected in the 23S-5S intergenetic region conserved for all Legionella spp. Two TaqMan probes were designed in the antisense strand of
the amplicon. One probe recognized all Legionella spp. and the other was Legionella pneumophila-speciﬁc. Both probes are quenched at the 3¢-end
by black hole quencher (BHQ), but labelled by different ﬂuorescent reporter molecules with distinct emission wavelength. (b) Real-time PCR
standard curves generated from L. pneumophila probe (upper panel) and Legionella spp. probe (lower panel). Seven ten-fold serial dilutions of Leg-
ionella genomic DNA were prepared for qPCR. The concentration of genomic DNA for each dilution ranged from 3 gEq to 3.0 E + 6 gEq per
PCR reaction. The standard curve equation, R2 value, and ampliﬁcation efﬁciency are indicated. (c) Gel analysis of the endpoint PCR product.
The amplicon derived from the PCR reaction that has the highest amount of the template (3.0 E + 6 gEq) was analysed on 4% E-gel (Invitrogen
Corp., Carlsbad, CA, USA) to assess ampliﬁcation speciﬁcity. Lane 1: 25-bp DNA ladder (Promega Corp., Madison, WI, USA). gEq, genome
equivalent; Ct, cycle threshold.
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clinically signiﬁcant. In recent years, molecular methods
based on nucleic acid testing (NAT) have been extensively
explored for diagnosis of LD. Overall NAT can be assigned
to four types of assay: (i) PCR ampliﬁcation of the whole
genome followed by restriction enzymatic digestion and gel
analysis [13,14]; (ii) PCR ampliﬁcation of speciﬁc regions of
the genome followed by sequencing analysis [15, 16]; (iii)
DNA hybridization or ﬂuorescent in situ hybridization (FISH)
[17–19], and (iv) real-time PCR assays targeting 16S rRNA,
the mip gene or the 23S-5S intergenetic region [20–23]. A
high rate of recombination in the 16S rRNA gene results in
multiple heterogeneous copies in the genome, which may
lead to erroneous species identiﬁcation [24,25]. The Legionel-
la mip gene is highly variable, which makes designing a
consensus probe to recognize all Legionella spp. virtually
impossible [9]. The relatively conserved 23S-5S region allows
the selection of primers and probes to detect L. pneumophila
and Legionella spp. in a singleplex format. Three singleplex
real-time PCR assays for identifying and differentiating
L. pneumophila from other Legionella spp. have been reported
[20–22]. These tests either require sequencing or melting
curve analysis to distinguish L. pneumophila from other
species, or lack speciﬁcity or validation using clinical
specimens [20–22].
The availability of suitable patient samples for Legionella
nucleic acid detection is limited. Oral pharyngeal swabs or
nasopharyngeal swabs that are routinely taken from patients
with respiratory infections may be less than ideal for Legionel-
la-speciﬁc PCR testing unless the burden of Legionellae is high
[26]. Collection of serum or urine samples is simple to
perform, but the reported sensitivity varies from 30% to
86% for urine samples [27–29] and is < 60% for serum
samples from patients with proven LD [30]. It appears that
Legionella DNA in serum only peaks in the acute stage of
infection [30]. In this study, the sensitivity observed with the
archived serum samples was < 30% (data not shown). Bronc-
hoalveolar lavage ﬂuid, bronchial aspirates, lung biopsies,
post-mortem tissue specimens and sputum appear to be
more suitable for culture and PCR, but most of these speci-
mens are not readily obtainable and are not usually taken for
diagnosis [6,31]. Nevertheless, these clinical specimens are
valuable for validation of this diagnostic assay. The level of
the impurities, such as human genomic DNA, protein and
carbohydrates, varies among different types of specimen, and
pathogen concentration in a clinical sample is signiﬁcantly
lower than that in laboratory cultures.
Culture provides deﬁnitive diagnosis and remains a refer-
ence standard for Legionellae identiﬁcation, but its use in the
diagnosis of LD continues to decline. The clinical samples
used in this study and in others [21–23] were positive only
for L. pneumophila, suggesting that some non-pneumophila
species were not detected by culture (L. cincinnatiensis,
L. longbeachae and L. micdadei). Serological testing is generally
limited to epidemiological studies and is unsuitable for diag-
nosis of acute LD because seroconversion does not occur
until 2 weeks after the onset of illness and may even be
absent in some patients [32].
In addition, the serological heterogeneity of Legionella spp.
and antibody cross-reactions can lead to false-negative or
false-positive results [33]. The goal of this study was to
develop a molecular assay as a supplemental tool for diagno-
sis of LD caused by Legionella spp.
The absence of unique clinical features or radiographic
patterns complicates the diagnosis of LD. Among the 149
TABLE 2. Legionella species used for evaluating the
23S-5S assay
Legionella spp. Strains, n
1 L. pneumophila 66
2 L. adelaidensis 1
3 L. anisa 18
4 L. beliardensis 1
5 L. birminghamensis 5
6 L. bozemanae 31
7 L. brunensis 1
8 L. busanensis 1
9 L. cherrii 3
10 L. cincinnatiensis 3
11 L. drozanskii 2
12 L. dumofﬁi 7
13 L. erythra 3
14 L. fairﬁeldensis 1
15 L. fallonii 2
16 L. feeleii 7
17 L. geestiana 1
18 L. genomo species 1
19 L. gormanii 4
20 L. gratiana 1
21 L. gresilensis 1
22 L. hackeliae 4
23 L. israelensis 1
24 L. jamestowniensis 2
25 L. jordanis 2
26 L. lansingensis 2
27 L. longbeachae 7
28 L. londiniensis 2
29 L. lytica 1
30 L. maceachernii 1
31 L. micdadei 6
32 L. moravica 1
33 L. nagasakii 2
34 L. nautarum 3
35 L. oakridgensis 3
36 L. parisiensis 2
37 L. quateirensis 3
38 L. quinlavanii 8
39 L. rowbothamii 2
40 L. rubriluscens 3
41 L. sainthelensis 6
42 L. santicrucis 1
43 L. shakespearei 3
44 L. spiritensis 3
45 L. steigerwaltii 1
46 L. taurinensis 2
47 L. tucsonensis 4
48 L. wadsworthii 2
49 L. waltersii 1
50 L. worsleiensis 2
Unidentiﬁed Legionella 31
Total 271
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lung specimens collected from patients with possible LD,
Legionella spp. was detected in only 44% of cases. It is possi-
ble that the infection in these patients was caused by other
pathogens. For example, we detected Pseudomonas aeruginosa,
Sphingomonas spp. and Eubacterium spp. in some culture-
negative samples using 16S rRNA PCR and sequencing
analysis (data not shown).
In conclusion, we have established a sensitive and speciﬁc
real-time PCR assay that allows the detection of L. pneumo-
phila and its differentiation from non-pneumophila species.
Use of this assay in conjunction with currently recommended
diagnostic tests should lead to increased rates of detection
of respiratory disease caused by Legionella species.
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